Word

NEMAURA

Status

Registered

Status Code

707

Status Date

Thursday, May 23, 2024

Serial Number

79185414

Registration Number

5293350

Registration Date

Tuesday, September 26, 2017

Mark Type

4

Filing Date

Thursday, December 24, 2015

Published for Opposition

Tuesday, July 11, 2017

Trademark Owner History

Nemaura Pharma Limited - Original Registrant

Classifications

5 [ Pharmaceutical and veterinary preparations for treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Sanitary preparations for medical purposes; Diagnostic preparations and substances for medical or veterinary purposes; Medical diagnostic reagents; Antiserums for medical or veterinary diagnostic purposes; Vaccines for human beings and animals; Adjuvants for use with vaccines; Biological laboratory preparations for medical and veterinary purposes for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Chemical preparations and reagents for medical, pharmaceutical and veterinary purposes for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Viruses for the treatment of humans and animals for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Diagnostic preparations for medical purposes; In-vitro diagnostics for medical purposes; In-vivo diagnostics for medical purposes; Medical plasters; Transdermal patches for use in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Transdermal plasters for use in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Transdermal therapeutic drug delivery systems (TTS), namely, transdermal patches and plasters treated or impregnated with pharmaceutical active ingredients for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Medicated transdermal drug delivery patches featuring medication for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Vaccines; Drug delivery agents in the form of dissolvable films, coatings for tablets, capsules that facilitate the delivery of pharmaceutical preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Pharmaceutical preparations for injection in the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Drug delivery agents in the form of liquid medications, tablets, powders, capsules, inhalants, nasal sprays, orally disintegrating tablets, and mouthwashes that facilitate the delivery of pharmaceutical preparations; Balms for medical purposes; Tonics for medical purposes, namely, for the treatment of diabetes, cardiovascular conditions, pulmonary conditions, skin conditions, infectious diseases, central nervous system disorders, metabolic disorders, cancer, and chronic pain; Disinfectants, antiseptics ]

10 [ Surgical apparatus and instruments for medical, dental or veterinary use; Suture materials; Inhalers for medical purposes; Filters for inhalers for medical purposes; Inhalers for medical use; Inhalers for therapeutic use; Electromagnetic drug delivery apparatus for medical use; Drug delivery apparatus and devices, namely, medical apparatus and units for dosage, measuring and monitoring; Microneedle arrays for delivering medications; Hypodermic syringes for injections for medical purposes; Electrical drug delivery apparatus for medical use; Needles for medical and surgical use; Hypodermic needles ]

42 Medical research services; Conducting clinical trials for others; Medical research laboratory services; Medical research laboratory services for the analysis of samples taken from patients; Scientific analysis and research services, namely, DNA analysis services for scientific research purposes; Product development relating to pharmaceuticals, medicines, medicaments and veterinary products; Medical and health care testing services for research purposes, namely, clinical testing services, physician testing services for assisting pharmacists, pharmaceutical testing services, and medical laboratory and testing services; Pharmaceutical research and development services; Medical and scientific research information in the field of healthcare; Cosmetics research; Design and development of computer hardware and software and information storage retrieval services in the fields of diagnostic testing and preparations for the treatment, monitoring or diagnosis of disease

Trademark Events

Apr 11, 2016

Assigned To Examiner

Mar 31, 2016

Sn Assigned For Sect 66a Appl From Ib

Apr 1, 2016

New Application Office Supplied Data Entered

Apr 5, 2016

Application Filing Receipt Mailed

Apr 21, 2016

Non-Final Action Written

Apr 22, 2016

Non-Final Action (Ib Refusal) Prepared For Review

Apr 22, 2016

Refusal Processed By Mpu

Apr 22, 2016

Non-Final Action Mailed - Refusal Sent To Ib

May 14, 2016

Refusal Processed By Ib

Oct 21, 2016

Teas Response To Office Action Received

Oct 21, 2016

Correspondence Received In Law Office

Oct 21, 2016

Teas/Email Correspondence Entered

Nov 14, 2016

Final Refusal Written

Nov 14, 2016

Final Refusal E-Mailed

Nov 14, 2016

Notification Of Final Refusal Emailed

Feb 2, 2017

Change Of Name/Address Rec'd From Ib

May 15, 2017

Teas Request For Reconsideration Received

May 15, 2017

Exparte Appeal Received At Ttab

May 15, 2017

Jurisdiction Restored To Examining Attorney

May 15, 2017

Ex Parte Appeal-Instituted

May 31, 2017

Examiners Amendment -Written

May 31, 2017

Examiners Amendment E-Mailed

May 31, 2017

Notification Of Examiners Amendment E-Mailed

May 31, 2017

Examiner's Amendment Entered

May 31, 2017

Approved For Pub - Principal Register

May 31, 2017

Exparte Appeal Terminated

Jun 21, 2017

Notification Of Notice Of Publication E-Mailed

Jul 11, 2017

Published For Opposition

Jun 21, 2017

Notice Of Start Of Opposition Period Created, To Be Sent To Ib

Jun 21, 2017

Notification Of Possible Opposition Sent To Ib

Jul 8, 2017

Notification Processed By Ib

Jul 11, 2017

Official Gazette Publication Confirmation E-Mailed

Aug 30, 2017

Notification Of Possible Opposition Created, To Be Sent To Ib

Aug 30, 2017

Notification Of Possible Opposition Sent To Ib

Sep 15, 2017

Notification Of Possible Opposition - Processed By Ib

Sep 26, 2017

Registered-Principal Register

Dec 1, 2017

New Representative At Ib Received

Dec 26, 2017

Final Disposition Notice Created, To Be Sent To Ib

Jan 12, 2018

Final Disposition Processed

Jan 12, 2018

Final Disposition Notice Sent To Ib

Feb 10, 2018

Final Decision Transaction Processed By Ib

Sep 26, 2022

Courtesy Reminder - Sec. 71 (6-Yr) E-Mailed

Sep 26, 2023

Teas Section 71 Received

May 20, 2024

Case Assigned To Post Registration Paralegal

May 23, 2024

Registered - Partial Sec 71 Accepted

May 23, 2024

Notice Of Acceptance Of Sec. 71 - E-Mailed